KRAS and non-small cell lung carcinoma: Targeted therapies blocking KRAS itself have not yet been developed, but recent studies targeting RAS signaling are promising.[48,49] Furthermore, colorectal cancer patients with a KRAS mutation respond less to EGFR-targeting drugs.[26] In non-small cell lung cancer, this association has not been demonstrated, but KRAS mutations are associated with worse prognosis.[50] The role of KRAS mutations in cervical AC remains to be investigated.